Inhibition of the anti-staphylococcal activity of the antiseptic polihexanide by mucin

被引:0
作者
Ansorg, R [1 ]
Rath, PM [1 ]
Fabry, W [1 ]
机构
[1] Univ Essen Gesamthsch, Inst Med Mikrobiol, D-45147 Essen, Germany
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2003年 / 53卷 / 05期
关键词
antiseptic; CAS; 28757-48-4; Lavasept; mucin; polihexanide; staphylococcus aureus;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The antiseptic Lavasept(R) (1,S), containing the polymeric biguanide polihexanide (CAS 28757-48-4), possesses microbicidal activity against a broad spectrum of bacteria including Staphylococcus aureus. It is used for antiseptic wound care in concentrations corresponding to 0.2-0.4 mg polihexanide per ml. To obtain basic data on its ability to eradicate S. aureus colonizing the nasal mucosa, the influence of mucin on the anti-staphylococcal activity was investigated. A disk agar-diffusion method was applied. Two reference strains of S. aureus (methicillin-sensitive S. aureus ATCC 29213 and methicillin-resistant S. aureus ATCC 33591) and 20 fresh clinical isolates were used. In the absence of mucin, the growth of all strains was inhibited by polihexanide concentrations of 0.1 mg/ml. In the presence of 0.25 % mucin in the test medium, a concentration of 0.4 mg/ml was necessary to inhibit all strains. Mucin concentrations of 0.5 % and I %, that are even lower than the mucin concentrations in healthy nasal secretions, abolished the activity of the therapeutic concentrations of polihexanide. It is concluded that the inactivation of LS by mucin obstructs a reliable clearance of nasal S. aureus carriage.
引用
收藏
页码:368 / 371
页数:4
相关论文
共 19 条
[1]   MUPIROCIN-RESISTANT STAPHYLOCOCCUS-AUREUS IN A SPECIALIST SCHOOL POPULATION [J].
CHATFIELD, CA ;
ONEILL, WA ;
COOKE, RPD ;
MCGHEE, KJ ;
ISSACK, M ;
RAHMAN, M ;
NOBLE, WC .
JOURNAL OF HOSPITAL INFECTION, 1994, 26 (04) :273-278
[2]   CHEMICAL ASPECTS OF MUCUS [J].
CLAMP, JR ;
ALLEN, A ;
GIBBONS, RA ;
ROBERTS, GP .
BRITISH MEDICAL BULLETIN, 1978, 34 (01) :25-41
[3]   MUPIROCIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
COOKSON, BD ;
LACEY, RW ;
NOBLE, WC ;
REEVES, DS ;
WISE, R ;
REDHEAD, RJ .
LANCET, 1990, 335 (8697) :1095-1096
[4]   Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus [J].
Harbarth, S ;
Dharan, S ;
Liassine, N ;
Herrault, P ;
Auckenthaler, R ;
Pittet, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1412-1416
[5]   THE EFFICACY OF INTRANASAL MUPIROCIN IN THE PREVENTION OF STAPHYLOCOCCAL INFECTIONS - A REVIEW OF RECENT EXPERIENCE [J].
HUDSON, IRB .
JOURNAL OF HOSPITAL INFECTION, 1994, 27 (02) :81-98
[6]   Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks [J].
Kluytmans, J ;
vanBelkum, A ;
Verbrugh, H .
CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (03) :505-+
[7]  
KOLAWOLE DO, 1984, FEMS MICROBIOL LETT, V25, P205
[8]   MUPIROCIN RESISTANCE AMONG CONSECUTIVE ISOLATES OF OXACILLIN-RESISTANT AND BORDERLINE OXACILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS AT A UNIVERSITY HOSPITAL [J].
LAYTON, MC ;
PATTERSON, JE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1664-1667
[9]   Medical progress -: Staphylococcus aureus infections [J].
Lowy, FD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (08) :520-532
[10]   Antiseptics and disinfectants: Activity, action, and resistance [J].
McDonnell, G ;
Russell, AD .
CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (01) :147-+